ReviewFrontiers in medicine2018
Ultraviolet-Based Pathogen Inactivation Systems: Untangling the Molecular Targets Activated in Platelets.
Review in Frontiers in medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 40 citations in OpenAlex.
- Increase of Phosphoprotein Expressions in Amotosalen/UVA-Treated Platelet Concentrates.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2024Article
- The Preclinical Validation of 405 nm Light Parasiticidal Efficacy onMicroorganisms · 2024Article
- Cold-stored platelets for acute bleeding in cardiac surgical patients: a narrative review.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2023Review
- Platelet concentrates in platelet additive solutions generate less complement activation products during storage than platelets stored in plasma.Blood transfusion = Trasfusione del sangue · 2023Article
- Platelet-derived immune-modulatory mediators and transfusion: time to consider their effects?Blood transfusion = Trasfusione del sangue · 2022Article
- In Vitro Comparative Study of Platelets Treated with Two Pathogen-Inactivation Methods to Extend Shelf Life to 7 Days.Pathogens (Basel, Switzerland) · 2022Article
- Human Platelet Lysate for Good Manufacturing Practice-Compliant Cell Production.International journal of molecular sciences · 2021Review
- Pathogen-reduced PRP blocks T-cell activation, induces Treg cells, and promotes TGF-β expression by cDCs and monocytes in mice.Blood advances · 2020Article
- Effects of amotosalen treatment on human platelet lysate bioactivity: A proof-of-concept study.PloS one · 2020Article
- Platelets treated with pathogen reduction technology: current status and future direction.F1000Research · 2020Review
- Pathogen reduction with riboflavin and ultraviolet light induces a quasi-apoptotic state in blood leukocytes.Transfusion · 2019Article
- Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026).Transfusion · 2019Article
- Assessment of dengue virus inactivation in random donor platelets using amotosalen and ultraviolet A illumination.Asian journal of transfusion scienceArticle
- Human leukocyte antigen alloimmunization prevention mechanisms in blood transfusion.Asian journal of transfusion scienceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transfusions of platelets are an important cornerstone of medicine; however, recipients may be subject to risk of adverse events associated with the potential transmission of pathogens, especially bacteria. Pathogen inactivation (PI) technologies based on ultraviolet illumination have been developed in the last decades to mitigate this risk. This review discusses studies of platelet concentrates treated with the current generation of PI technologies to assess their impact on quality, PI capacity, safety, and clinical efficacy. Improved safety seems to come with the cost of reduced platelet functionality, and hence transfusion efficacy. In order to understand these negative impacts in more detail, several molecular analyses have identified signaling pathways linked to platelet function that are altered by PI. Because some of these biochemical alterations are similar to those seen arising in the context of routine platelet storage lesion development occurring during blood bank storage, we lack a complete picture of the contribution of PI treatment to impaired platelet functionality. A model generated using data from currently available publications places the signaling protein kinase p38 as a central player regulating a variety of mechanisms triggered in platelets by PI systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.